WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder

Christer Allgulander, Borwin Bandelow, Eric Hollander, Stuart A. Montgomery, David J. Nutt, Ahmed Okasha, Mark H. Pollack, Dan J. Stein, Richard P. Swinson

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

What are the current recommendations for the long-term treatment of generalized anxiety disorder (GAD)? GAD is a common disorder with a lifetime prevalence of 4% to 7% in the general population. GAD is characterized by excessive, uncontrollable worry or anxiety about a number of events or activities that the individual experiences on more days than not over a 6-month period. Onset of GAD symptoms usually occurs during an individual's early twenties; however, high rates of GAD have also been seen in children and adolescents. The clinical course of GAD is often chronic, with 40% of patients reporting illness lasting >5 years. GAD is associated with pronounced functional impairment, resulting in decreased vocational function and reduced quality of life. Patients with GAD tend to be high users of outpatient medical care, which contributes significantly to health-care costs. Currently, benzodiazepines and buspirone are prescribed frequently to treat GAD. Although both show efficacy in acute treatment trials, few long-term studies have been performed. Benzodiazepines are not recommended for long-term treatment of GAD, due to associated development of tolerance, psychomotor impairment, cognitive and memory changes, physical dependence, and a withdrawal reaction on discontinuation. The antidepressant venlafaxine extended-release (XR) has received approval for the treatment of GAD in the United States and many other countries. Venlafaxine XR has demonstrated efficacy over placebo in two randomized treatment trials of 6 months' duration as well as in other acute trials. Paroxetine is the first of the selective serotonin reuptake inhibitors (SSRIs) to receive US approval for the treatment of GAD. Paroxetine demonstrated superiority to placebo in short-term trials, and investigations into the use of other SSRIs are ongoing. This suggests that other SSRIs, and serotonin and noradrenaline reuptake inhibitors, are likely to be effective in the treatment of GAD. Of the psychological therapies, cognitive-behavioral therapy (CBT) shows the greatest benefit in treating GAD patients. Treatment gains after a 12-week course of CBT may be maintained for up to 1 year. Currently, no guidelines exist for the long-term treatment of GAD.

Original languageEnglish (US)
Pages (from-to)53-61
Number of pages9
JournalCNS Spectrums
Volume8
Issue number8 SUPPL. 1
StatePublished - Aug 2003
Externally publishedYes

Fingerprint

Anxiety Disorders
Therapeutics
Serotonin Uptake Inhibitors
Paroxetine
Cognitive Therapy
Benzodiazepines
Psychomotor Disorders
Placebos
Buspirone
Ambulatory Care
Health Care Costs
Antidepressive Agents
Anxiety

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology

Cite this

Allgulander, C., Bandelow, B., Hollander, E., Montgomery, S. A., Nutt, D. J., Okasha, A., ... Swinson, R. P. (2003). WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder. CNS Spectrums, 8(8 SUPPL. 1), 53-61.

WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder. / Allgulander, Christer; Bandelow, Borwin; Hollander, Eric; Montgomery, Stuart A.; Nutt, David J.; Okasha, Ahmed; Pollack, Mark H.; Stein, Dan J.; Swinson, Richard P.

In: CNS Spectrums, Vol. 8, No. 8 SUPPL. 1, 08.2003, p. 53-61.

Research output: Contribution to journalArticle

Allgulander, C, Bandelow, B, Hollander, E, Montgomery, SA, Nutt, DJ, Okasha, A, Pollack, MH, Stein, DJ & Swinson, RP 2003, 'WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder', CNS Spectrums, vol. 8, no. 8 SUPPL. 1, pp. 53-61.
Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A et al. WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder. CNS Spectrums. 2003 Aug;8(8 SUPPL. 1):53-61.
Allgulander, Christer ; Bandelow, Borwin ; Hollander, Eric ; Montgomery, Stuart A. ; Nutt, David J. ; Okasha, Ahmed ; Pollack, Mark H. ; Stein, Dan J. ; Swinson, Richard P. / WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder. In: CNS Spectrums. 2003 ; Vol. 8, No. 8 SUPPL. 1. pp. 53-61.
@article{f8cd702d7a6e40afb04351f933bde27c,
title = "WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder",
abstract = "What are the current recommendations for the long-term treatment of generalized anxiety disorder (GAD)? GAD is a common disorder with a lifetime prevalence of 4{\%} to 7{\%} in the general population. GAD is characterized by excessive, uncontrollable worry or anxiety about a number of events or activities that the individual experiences on more days than not over a 6-month period. Onset of GAD symptoms usually occurs during an individual's early twenties; however, high rates of GAD have also been seen in children and adolescents. The clinical course of GAD is often chronic, with 40{\%} of patients reporting illness lasting >5 years. GAD is associated with pronounced functional impairment, resulting in decreased vocational function and reduced quality of life. Patients with GAD tend to be high users of outpatient medical care, which contributes significantly to health-care costs. Currently, benzodiazepines and buspirone are prescribed frequently to treat GAD. Although both show efficacy in acute treatment trials, few long-term studies have been performed. Benzodiazepines are not recommended for long-term treatment of GAD, due to associated development of tolerance, psychomotor impairment, cognitive and memory changes, physical dependence, and a withdrawal reaction on discontinuation. The antidepressant venlafaxine extended-release (XR) has received approval for the treatment of GAD in the United States and many other countries. Venlafaxine XR has demonstrated efficacy over placebo in two randomized treatment trials of 6 months' duration as well as in other acute trials. Paroxetine is the first of the selective serotonin reuptake inhibitors (SSRIs) to receive US approval for the treatment of GAD. Paroxetine demonstrated superiority to placebo in short-term trials, and investigations into the use of other SSRIs are ongoing. This suggests that other SSRIs, and serotonin and noradrenaline reuptake inhibitors, are likely to be effective in the treatment of GAD. Of the psychological therapies, cognitive-behavioral therapy (CBT) shows the greatest benefit in treating GAD patients. Treatment gains after a 12-week course of CBT may be maintained for up to 1 year. Currently, no guidelines exist for the long-term treatment of GAD.",
author = "Christer Allgulander and Borwin Bandelow and Eric Hollander and Montgomery, {Stuart A.} and Nutt, {David J.} and Ahmed Okasha and Pollack, {Mark H.} and Stein, {Dan J.} and Swinson, {Richard P.}",
year = "2003",
month = "8",
language = "English (US)",
volume = "8",
pages = "53--61",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "8 SUPPL. 1",

}

TY - JOUR

T1 - WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder

AU - Allgulander, Christer

AU - Bandelow, Borwin

AU - Hollander, Eric

AU - Montgomery, Stuart A.

AU - Nutt, David J.

AU - Okasha, Ahmed

AU - Pollack, Mark H.

AU - Stein, Dan J.

AU - Swinson, Richard P.

PY - 2003/8

Y1 - 2003/8

N2 - What are the current recommendations for the long-term treatment of generalized anxiety disorder (GAD)? GAD is a common disorder with a lifetime prevalence of 4% to 7% in the general population. GAD is characterized by excessive, uncontrollable worry or anxiety about a number of events or activities that the individual experiences on more days than not over a 6-month period. Onset of GAD symptoms usually occurs during an individual's early twenties; however, high rates of GAD have also been seen in children and adolescents. The clinical course of GAD is often chronic, with 40% of patients reporting illness lasting >5 years. GAD is associated with pronounced functional impairment, resulting in decreased vocational function and reduced quality of life. Patients with GAD tend to be high users of outpatient medical care, which contributes significantly to health-care costs. Currently, benzodiazepines and buspirone are prescribed frequently to treat GAD. Although both show efficacy in acute treatment trials, few long-term studies have been performed. Benzodiazepines are not recommended for long-term treatment of GAD, due to associated development of tolerance, psychomotor impairment, cognitive and memory changes, physical dependence, and a withdrawal reaction on discontinuation. The antidepressant venlafaxine extended-release (XR) has received approval for the treatment of GAD in the United States and many other countries. Venlafaxine XR has demonstrated efficacy over placebo in two randomized treatment trials of 6 months' duration as well as in other acute trials. Paroxetine is the first of the selective serotonin reuptake inhibitors (SSRIs) to receive US approval for the treatment of GAD. Paroxetine demonstrated superiority to placebo in short-term trials, and investigations into the use of other SSRIs are ongoing. This suggests that other SSRIs, and serotonin and noradrenaline reuptake inhibitors, are likely to be effective in the treatment of GAD. Of the psychological therapies, cognitive-behavioral therapy (CBT) shows the greatest benefit in treating GAD patients. Treatment gains after a 12-week course of CBT may be maintained for up to 1 year. Currently, no guidelines exist for the long-term treatment of GAD.

AB - What are the current recommendations for the long-term treatment of generalized anxiety disorder (GAD)? GAD is a common disorder with a lifetime prevalence of 4% to 7% in the general population. GAD is characterized by excessive, uncontrollable worry or anxiety about a number of events or activities that the individual experiences on more days than not over a 6-month period. Onset of GAD symptoms usually occurs during an individual's early twenties; however, high rates of GAD have also been seen in children and adolescents. The clinical course of GAD is often chronic, with 40% of patients reporting illness lasting >5 years. GAD is associated with pronounced functional impairment, resulting in decreased vocational function and reduced quality of life. Patients with GAD tend to be high users of outpatient medical care, which contributes significantly to health-care costs. Currently, benzodiazepines and buspirone are prescribed frequently to treat GAD. Although both show efficacy in acute treatment trials, few long-term studies have been performed. Benzodiazepines are not recommended for long-term treatment of GAD, due to associated development of tolerance, psychomotor impairment, cognitive and memory changes, physical dependence, and a withdrawal reaction on discontinuation. The antidepressant venlafaxine extended-release (XR) has received approval for the treatment of GAD in the United States and many other countries. Venlafaxine XR has demonstrated efficacy over placebo in two randomized treatment trials of 6 months' duration as well as in other acute trials. Paroxetine is the first of the selective serotonin reuptake inhibitors (SSRIs) to receive US approval for the treatment of GAD. Paroxetine demonstrated superiority to placebo in short-term trials, and investigations into the use of other SSRIs are ongoing. This suggests that other SSRIs, and serotonin and noradrenaline reuptake inhibitors, are likely to be effective in the treatment of GAD. Of the psychological therapies, cognitive-behavioral therapy (CBT) shows the greatest benefit in treating GAD patients. Treatment gains after a 12-week course of CBT may be maintained for up to 1 year. Currently, no guidelines exist for the long-term treatment of GAD.

UR - http://www.scopus.com/inward/record.url?scp=1542319760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542319760&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 53

EP - 61

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 8 SUPPL. 1

ER -